SEARCH

SEARCH BY CITATION

References

  • 1
    Yang W, Israni RK, Brunelli SM, Joffe MM, Fishbane S, Feldman HI. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 2007; 18: 31643170.
  • 2
    Ebben JP, Gilbertson DT, Foley RN, Collins AJ. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 2006; 1: 12051210.
  • 3
    Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 2005; 68: 13371343.
  • 4
    Lacson E Jr, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis 2003; 41: 111124.
  • 5
    Berns JS, Elzein H, Lynn RI, Fishbane S, Meisels IS, Deoreo PB. Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int 2003; 64: 15141521.
  • 6
    Weinhandl ED, Peng Y, Gilbertson DT, Bradbury BD, Collins AJ. Hemoglobin variability and mortality: confounding by disease severity. Am J Kidney Dis 2010; 57: 255265.
  • 7
    Brunelli SM, Lynch KE, Ankers ED, Joffe MM, Yang W, Thadhani RI, Feldman HI. Association of hemoglobin variability and mortality among contemporary incident hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 17331740.
  • 8
    Eckardt KU, Kim J, Kronenberg F, Aljama P, Anker SD, Canaud B, Molemans B, Stenvinkel P, Schernthaner G, Ireland E, Fouqueray B, Macdougall IC. Hemoglobin variability does not predict mortality in European hemodialysis patients. J Am Soc Nephrol 2010; 21: 17651775.
  • 9
    Spiegel DM. Hemoglobin variability in chronic kidney disease: a cross-sectional study. Am J Med Sci 2009; 337: 340343.
  • 10
    Schiller B, Besarab A. Simplifying anemia management in hemodialysis patients: ESAs administered at longer dosing intervals can enhance opportunities to provide patient-focused care. Curr Med Res Opin 2011; 27: 15391550.
  • 11
    Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007; 2: 637646.
  • 12
    Klinger M, Arias M, Vargemezis V, Besarab A, Sulowicz W, Gerntholtz T, Ciechanowski K, Dougherty FC, Beyer U. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. Am J Kidney Dis 2007; 50: 9891000.
  • 13
    Kessler M, Martinez-Castelao A, Siamopoulos KC, Villa G, Spinowitz B, Dougherty FC, Beyer U. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: the ARCTOS extension study. Hemodial Int 2010; 14: 233239.
  • 14
    Sutton A, Ades AE, Cooper N, Abrams K. Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics 2008; 26: 753767.
  • 15
    European Medicines Agency. Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant erythropoietins (Revision). 2010.
  • 16
    Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions 5.0. 1 [updated September 2008]. The Cochrane Collaboration, 2008. Available at http://www.cochrane-handbook.org (last accessed 2 August 2012).
  • 17
    Martin KJ. The first human cell line-derived erythropoietin, epoetin-delta (Dynepo), in the management of anemia in patients with chronic kidney disease. Clin Nephrol 2007; 68: 2631.
  • 18
    Levin NW, Fishbane S, Canedo FV, Zeig S, Nassar GM, Moran JE, Villa G, Beyer U, Oguey D. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 2007; 370: 14151421.
  • 19
    Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, Greenland S, Kalantar-Zadeh K. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006; 17: 11811191.
  • 20
    Pisoni RL, Bragg-Gresham JL, Fuller DS, Morgenstern H, Canaud B, Locatelli F, Li Y, Gillespie B, Wolfe RA, Port FK, Robinson BM. Facility-level interpatient hemoglobin variability in hemodialysis centers participating in the Dialysis Outcomes and Practice Patterns Study (DOPPS): associations with mortality, patient characteristics, and facility practices. Am J Kidney Dis 2011; 57: 266275.
  • 21
    Mandema JW, Cox E, Alderman J. Therapeutic benefit of eletriptan compared to sumatriptan for the acute relief of migraine pain – results of a model-based meta-analysis that accounts for encapsulation. Cephalalgia 2005; 25: 715725.
  • 22
    Jansen JP, Bergman GJ, Huels J, Olson M. Prevention of vertebral fractures in osteoporosis: mixed treatment comparison of bisphosphonate therapies. Curr Med Res Opin 2009; 25: 18611868.
  • 23
    Bousquet J, Ben-Joseph R, Messonnier M, Alemao E, Gould AL. A meta-analysis of the dose-response relationship of inhaled corticosteroids in adolescents and adults with mild to moderate persistent asthma. Clin Ther 2002; 24: 120.
  • 24
    Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 2004; 24: 192208.
  • 25
    Weinhandl ED, Peng Y, Gilbertson DT, Bradbury BD, Collins AJ. Hemoglobin variability and mortality: confounding by disease severity. Am J Kidney Dis 2011; 57: 255265.
  • 26
    Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, Vaamonde CA. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med 1998; 339: 578583.
  • 27
    Chanu P, Gieschke R, Charoin JE, Pannier A, Reigner B. Population pharmacokinetic/pharmacodynamic model for C.E.R.A. in both ESA-naive and ESA-treated chronic kidney disease patients with renal anemia. J Clin Pharmacol 2010; 50: 507520.
  • 28
    Carrera F, Lok CE, de Francisco A, Locatelli F, Mann JF, Canaud B, Kerr PG, Macdougall IC, Besarab A, Villa G, Kazes I, Van Vlem B, Jolly S, Beyer U, Dougherty FC. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrol Dial Transplant 2010; 25: 40094017.
  • 29
    Richardson D, Bartlett C, Will EJ. Intervention thresholds and ceilings can determine the haemoglobin outcome distribution in a haemodialysis population. Nephrol Dial Transplant 2000; 15: 20072013.
  • 30
    Brimble KS, Clase CM. Hemoglobin variability in dialysis patients. J Am Soc Nephrol 2007; 18: 22182220.
  • 31
    Kalantar-Zadeh K, Aronoff GR. Hemoglobin variability in anemia of chronic kidney disease. J Am Soc Nephrol 2009; 20: 479487.
  • 32
    van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 2002; 21: 589624.
  • 33
    Pisoni RL, Bragg-Gresham JL, Young EW, Akizawa T, Asano Y, Locatelli F, Bommer J, Cruz JM, Kerr PG, Mendelssohn DC, Held PJ, Port FK. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44: 94111.
  • 34
    Pisoni RL, Young EW, Dykstra DM, Greenwood RN, Hecking E, Gillespie B, Wolfe RA, Goodkin DA, Held PJ. Vascular access use in Europe and the United States: results from the DOPPS. Kidney Int 2002; 61: 305316.
  • 35
    De Meester J, Maes B, De Vriese A, De Moor B, Donck J, Helbert M, Bammens B, Jamar S. Fluctuations of haemoglobinaemia in chronic haemodialysis patients. Acta Clin Belg 2011; 66: 123128.
  • 36
    Khan I, Krishnan M, Kothawala A, Ashfaq A. Association of dialysis facility-level hemoglobin measurement and erythropoiesis-stimulating agent dose adjustment frequencies with dialysis facility-level hemoglobin variation: a retrospective analysis. BMC Nephrol 2011; 12: 2229.
  • 37
    Krivoshiev S, Wizemann V, Czekalski S, Schiller A, Pljesa S, Wolf-Pflugmann M, Siebert-Weigel M, Koytchev R, Bronn A. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia. Adv Ther 2010; 27: 105117.
  • 38
    Nagaya H, Inaguma D, Kitagawa A, Murata M, Kamimura Y, Hamaguchi K, Tatematsu M, Suzuki S, Kurata K, Yuzawa Y, Matsuo S. Intravenously administered darbepoetin alfa once a week could maintain hemoglobin level more efficiently than once every 2 weeks in patients on hemodialysis. Clin Exp Nephrol 2010; 14: 158163.
  • 39
    Haag-Weber M, Vetter A, Thyroff-Friesinger U. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. Clin Nephrol 2009; 72: 380390.
  • 40
    Abseamed, INN-epoetin alfa. EPAR-Assessment_Report. 2007 Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000727/WC500020666.pdf (last accessed 2 August 2012).
  • 41
    Li WY, Chu TS, Huang JW, Wu MS, Wu KD. Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis. J Formos Med Assoc 2008; 107: 843850.
  • 42
    Locatelli F, Villa G, Messa P, Filippini A, Cannella G, De Ferrari G, Naso A, Rossi E, Formica M, Lombardi L, Rotolo U, Conte F. Efficacy and safety of once-weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients. J Nephrol 2008; 21: 412420.
  • 43
    Canaud B, Mingardi G, Braun J, Aljama P, Kerr PG, Locatelli F, Villa G, Van Vlem B, McMahon AW, Kerloeguen C, Beyer U. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial Transplant 2008; 23: 36543661.
  • 44
    Krivoshiev S, Todorov VV, Manitius J, Czekalski S, Scigalla P, Koytchev R. Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia. Curr Med Res Opin 2008; 24: 14071415.
  • 45
    Spinowitz B, Coyne DW, Lok CE, Fraticelli M, Azer M, Dalal S, Villa G, Rosansky S, Adamis H, Beyer U. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. Am J Nephrol 2008; 28: 280289.
  • 46
    Mircescu G, Garneata L, Ciocalteu A, Golea O, Gherman-Caprioara M, Capsa D, Mota E, Gusbeth-Tatomir P, Ghenu A, Baluta S, Constantinovici N, Covic AC. Once-every-2-week and once-weekly epoetin beta regimens: equivalency in hemodialyzed patients. Am J Kidney Dis 2006; 48: 445455.
  • 47
    Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, Picarello N, McDermott-Vitak A, Maroni BJ. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002; 40: 110118.
  • 48
    Vanrenterghem Y, Barany P, Mann JF, Kerr PG, Wilson J, Baker NF, Gray SJ. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 2002; 62: 21672175.
  • 49
    Weiss LG, Clyne N, Divino Fihlho J, Frisenette-Fich C, Kurkus J, Svensson B. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin beta: results from a randomized controlled multicentre trial. Swedish Study Group. Nephrol Dial Transplant 2000; 15: 20142019.